Iftekhar Khan

2.6k total citations
49 papers, 1.3k citations indexed

About

Iftekhar Khan is a scholar working on Economics and Econometrics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Iftekhar Khan has authored 49 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Economics and Econometrics, 13 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Iftekhar Khan's work include Health Systems, Economic Evaluations, Quality of Life (14 papers), Statistical Methods in Clinical Trials (7 papers) and Oral microbiology and periodontitis research (4 papers). Iftekhar Khan is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (14 papers), Statistical Methods in Clinical Trials (7 papers) and Oral microbiology and periodontitis research (4 papers). Iftekhar Khan collaborates with scholars based in United Kingdom, United States and Netherlands. Iftekhar Khan's co-authors include Ranjit Lall, Sarah E Lamb, Stavros Petrou, Stephen Morris, Dipesh Mistry, Bart Sheehan, Nicky Atherton, Vivien Nichols, Sukhdeep Dosanjh and Allan Hackshaw and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Iftekhar Khan

48 papers receiving 1.3k citations

Peers

Countries citing papers authored by Iftekhar Khan

Since Specialization

Citations

This map shows the geographic impact of Iftekhar Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iftekhar Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iftekhar Khan more than expected).

Fields of papers citing papers by Iftekhar Khan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iftekhar Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iftekhar Khan. The network helps show where Iftekhar Khan may publish in the future.

Co-authorship network of co-authors of Iftekhar Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Iftekhar Khan. A scholar is included among the top collaborators of Iftekhar Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iftekhar Khan. Iftekhar Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Artificial Intelligence in European Medicines Regulation: From Vision to Action. Harnessing the Capabilities of Artificial Intelligence for the Benefit of Public and Animal Health 2024 ·Clinical Pharmacology & Therapeutics ·(unknown), Peter Arlett, Kit C. B. Roes, Flora T. Musuamba, Gabriel Westman, (unknown), (unknown), (unknown), Iftekhar Khan, (unknown), Karl Broich, Emer Cooke	2
2	Persistent Exaggerated Granulomatous Hypersensitivity Reaction to Mycobacterium indicus pranii Immunomodulatory Therapy for COVID-19 Sepsis 2023 ·Indian Journal of Dermatology ·(unknown), (unknown), Iftekhar Khan, Neena Khanna	1
3	Comparative efficacy of self-administered dentifrices for the management of dentine hypersensitivity – A systematic review and network meta-analysis 2023 ·Journal of Dentistry ·A Pollard, Iftekhar Khan, Maria Davies, N. Claydon, Nicola West	7
4	A pilot study to evaluate the impact of digital imaging on the delivery of oral hygiene instruction 2022 ·Journal of Dentistry ·(unknown), Joon Seong, N. Claydon, Maria Davies, (unknown), Iftekhar Khan, Nicola West	5
5	Randomised controlled trial demonstrating the impact of behaviour change intervention provided by dental professionals to improve gingival health 2021 ·Journal of Dentistry ·(unknown), Maria Davies, Claire McCarthy, Iftekhar Khan, N. Claydon, Nicola West	2
6	Protocol for A randomised feasibility trial comparing fluoride interventions to prevent dental decay in older people in care homes (FInCH trial) 2021 ·BMC Oral Health ·Rakhee Patel, Iftekhar Khan, Mark Pennington, Nigel Pitts, C. Robertson, Jennifer E. Gallagher	4
7	Protocol for a randomised controlled trial of Subacromial spacer for Tears Affecting Rotator cuff Tendons: a Randomised, Efficient, Adaptive Clinical Trial in Surgery (START:REACTS) 2020 ·BMJ Open ·Andrew Metcalfe, Elke Gemperlé Mannion, Helen Parsons, Jaclyn Brown, Nick Parsons, (unknown), Rebecca Kearney, Tom Lawrence, Howard S. Bush, Kerri McGowan, Iftekhar Khan, James Mason, Charles Hutchinson, Simon Gates, Nigel Stallard, Martin Underwood, Steve Drew	10
8	Is Protocolised Weaning that Includes Early Extubation Onto Non-Invasive Ventilation More Cost Effective Than Protocolised Weaning Without Non-Invasive Ventilation? Findings from the Breathe Study 2020 ·PharmacoEconomics - Open ·(unknown), Iftekhar Khan, Mandy Maredza, Melina Dritsaki, Dipesh Mistry, Ranjit Lall, Sarah E Lamb, Keith Couper, Simon Gates, Gavin D. Perkins, Stavros Petrou	4
9	Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial 2018 ·BMJ ·Sarah E Lamb, Bart Sheehan, Nicky Atherton, Vivien Nichols, Helen Collins, Dipesh Mistry, Sukhdeep Dosanjh, Anne‐Marie Slowther, Iftekhar Khan, Stavros Petrou, Ranjit Lall	258
10	Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma 2016 ·PLoS ONE ·Nicholas F. Brown, Catherine McBain, Stephen Nash, Kirsten Hopkins, Paul Sanghera, Frank Saran, (unknown), (unknown), Laura Clifton‐Hadley, (unknown), Daniel Krell, (unknown), Iftekhar Khan, Paul Smith, Paul Mulholland	47
11	Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy 2015 ·BMJ Open ·Iftekhar Khan, Stephen Morris, Allan Hackshaw, Siow Ming Lee	14
12	Interpreting small treatment differences from quality of life data in cancer trials: an alternative measure of treatment benefit and effect size for the EORTC-QLQ-C30 2015 ·Health and Quality of Life Outcomes ·Iftekhar Khan, Zahid Bashir, Martin Förster	7
13	A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer 2014 ·Annals of Oncology ·Iain A. McNeish, JA Ledermann, (unknown), Lisa M. James, Stuart Kaye, Marcia Hall, Geoff Hall, Andrew R. Clamp, Helena Earl, Susana Banerjee, (unknown), F. Raja, A Feeney, (unknown), (unknown), Mojca Persic, Iftekhar Khan	64
14	Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control 2014 ·Molecular Oncology ·(unknown), Laura A. Tookman, (unknown), Katrina Pirlo, Rosalind Cutts, (unknown), (unknown), Elaine Leung, Suzanne Dowson, (unknown), Iftekhar Khan, Darren Ennis, Nelofer Syed, Tim Crook, James D. Brenton, Michelle Lockley, Iain A. McNeish	30
15	A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches 2014 ·Health and Quality of Life Outcomes ·Iftekhar Khan, Stephen Morris	34
16	A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework 2013 ·Computer Methods and Programs in Biomedicine ·Shah‐Jalal Sarker, Anne Whitehead, Iftekhar Khan	5
17	Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis 2012 ·Journal of Medical Economics ·W. Dunlop, Reiner Uhl, Iftekhar Khan, Anna M.W. Taylor, Garry Barton	43
18	First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial 2012 ·The Lancet Oncology ·Siow Ming Lee, Iftekhar Khan, Sunil Upadhyay, C. Lewanski, Stephen Falk, G. Skailes, Ernie Marshall, Penella J. Woll, M. Hatton, Rohit Lal, Richard C. Jones, Elizabeth Toy, David Chao, Gary Middleton, (unknown), Yenting Ngai, Robin Rudd, Allan Hackshaw, Chris Boshoff	133
19	Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies 2012 ·British Journal of Cancer ·Mark Jitlal, Iftekhar Khan, Siow Ming Lee, Allan Hackshaw	31
20	Incidence of Adverse Events During Prehospital Rapid Sequence Intubation: A Review of One Year on the London Helicopter Emergency Medical Service 2008 ·The Journal of Trauma: Injury, Infection, and Critical Care ·(unknown), (unknown), Iftekhar Khan	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact